Anodyne

Gabapentin
Gabapentin
Salts
[]
Gabapentin hydrochloride
Gabapentin hydrochloride
Gabapentin hydrobromide
Gabapentin hydrobromide
Molecular structure via molpic
Enable javascript to view conformer structure via 3Dmol.js
Molecular formulaC9H17NO2[1]
Molecular mass171.24 g/mol[1]
AppearanceWhite to off-white crystalline solid; crystals from ethanol/ether[1]
TasteBitter[1]
Predicted LogP-1.1[1]
Melting point162-166 °C; also reported as 165-167 °C[1]
DecompositionHazardous decomposition products formed under fire conditions - Carbon oxides, nitrogen oxides (NOx).[1]
Solubility>25.7 [ug/mL] (The mean of the results at pH 7.4)[1]
Chiralityachiral[2]
Identifiers
[]
IUPAC name2-[1-(aminomethyl)cyclohexyl]acetic acid[1]
SMILESC1CCC(CC1)(CC(=O)O)CN[1]
InChIInChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)[1]
InChIKeyUGJMXCAKCUNAIE-UHFFFAOYSA-N[1]
Dosing
Elimination half-life5 - 7 hours

Gabapentin

Gabapentin (also known as Gabapentine, 1-(Aminomethyl)cyclohexaneacetic acid, Aclonium, Gabapetin, Gabapentinum, gabapentina, Gabapentino, Fanatrex, Gralise or Serada) is a substance of the gabapentinoid class.

Chemistry

Gabapentin is typically found in the form of its hydrochloride and hydrobromide salts.

Stereochemistry

Gabapentin is a achiral mixture

Subjective effects

Experience reports

There are currently 25+ experience reports involving gabapentin on OpenErowid: []

See also

References

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 3446, Gabapentin. Accessed June 26, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/3446

  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Gabapentin. UNII: 6CW7F3G59X. Global Substance Registration System. Accessed June 26, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6CW7F3G59X

  3. Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. June 21, 2022. Accessed June 26, 2025. https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017